Analyst Ratings For Collegium Pharmaceutical (NASDAQ:COLL)
Today, William Blair reiterated its Outperform rating on Collegium Pharmaceutical (NASDAQ:COLL).
Some recent analyst ratings include
- 3/8/2018-William Blair Reiterated Rating of Outperform.
- 9/13/2016-Gabelli initiated coverage with a Buy rating.
Recent Insider Trading Activity For Collegium Pharmaceutical (NASDAQ:COLL)
Collegium Pharmaceutical (NASDAQ:COLL) has insider ownership of 25.76% and institutional ownership of 87.60%.
- On 1/23/2018 Michael Thomas Heffernan, Chairman, sold 20,000 with an average share price of $25.01 per share and the total transaction amounting to $500,200.00.
- On 1/19/2018 Michael Thomas Heffernan, Chairman, sold 20,000 with an average share price of $22.50 per share and the total transaction amounting to $450,000.00.
- On 1/10/2018 Alison B Fleming, Insider, sold 6,928 with an average share price of $19.07 per share and the total transaction amounting to $132,116.96.
- On 12/8/2017 Longitude Capital Partners, Ll, Major Shareholder, sold 1,000,000 with an average share price of $17.34 per share and the total transaction amounting to $17,340,000.00.
- On 11/21/2017 Alison B Fleming, Insider, sold 4,601 with an average share price of $17.25 per share and the total transaction amounting to $79,367.25.
- On 11/17/2017 Alison B Fleming, CTO, sold 4,029 with an average share price of $17.00 per share and the total transaction amounting to $68,493.00.
- On 11/15/2017 Michael Thomas Heffernan, CEO, sold 50,000 with an average share price of $15.53 per share and the total transaction amounting to $776,500.00.
Recent Trading Activity for Collegium Pharmaceutical (NASDAQ:COLL)
Shares of Collegium Pharmaceutical closed the previous trading session at 24.99 up +1.23 5.18% with 26.100000381469727 shares trading hands.